The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

One of the most agonizing experiences a cancer patient suffers is waiting without knowing: waiting for a diagnosis, waiting ...

A new drug delivery system shows promise for treating a rare, aggressive form of cancer affecting pregnant women and new ...

Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on ...

The following is a summary of “Future Directions in the Evaluation and Management of newly diagnosed metastatic cancer,” ...

Compared with endocrine therapy, radiotherapy was associated with a smaller reduction in health-related quality-of-life in ...

Laurie Ratliff was diagnosed with metastatic breast cancer 25 years ago, and she’s continuing to beat the odds while ...

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.

The leading Triple Negative Breast Cancer Companies such as Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 ...